Gene · 8317
NIH grants1,079
NIH grants whose papers are about the gene, through NIH's grant-paper links.
121 to 140 of 1,079
Download this page as JSON| Grant | Title | CDC7 papers | Newest fiscal year |
|---|---|---|---|
| R01CA159859 | Dysregulation of the Core Binding Factor Complex Inhibits Differentiation and Drives Group 4 Medulloblastoma | 1 | 2025 |
| R01CA197774 | Regulation of DNA synthesis in response to DNA damage | 1 | 2025 |
| R01CA205224 | EEPD1 Repair of Stressed Replication Forks | 1 | 2025 |
| R01CA233481 | PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS | 1 | 2025 |
| R01CA233626 | The function of the PRMT5 methylosome in MTAP deleted cancers | 1 | 2025 |
| R01CA237263 | DNA replication stress in cancer | 1 | 2025 |
| R01CA239161 | Mechanisms and Functions of ATR signaling | 1 | 2025 |
| R01CA258584 | Applying deep learning to predict T cell receptor binding specificity of neoantigens and response to checkpoint inhibitors | 1 | 2025 |
| R01CA259001 | Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells | 1 | 2025 |
| R01CA264078 | Drivers of histologic transformation in EGFR-mutant lung cancer | 1 | 2025 |
| R01CA264600 | Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment | 1 | 2025 |
| R01CA266046 | Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas. | 1 | 2025 |
| R01CA266172 | DNA damage response and cancer immunity | 1 | 2025 |
| R01CA266600 | EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA | 1 | 2025 |
| R01CA271595 | The non-catalytic function of PARP2 in DNA repair and cancer therapy | 1 | 2025 |
| R01CA275184 | The role of DNA-PKcs in DNA repair, lymphocyte development, RNA metabolism and tumor suppression | 1 | 2025 |
| R01CA282036 | The role of long noncoding RNA CRNDE in normal physiology and cancer | 1 | 2025 |
| R01ES026184 | The Role of Mono-ADP-Ribosylation by PARP14 in Radioresistance | 1 | 2025 |
| R01ES028271 | Investigation of human DNA polymerase epsilon variants | 1 | 2025 |
| R01ES031658 | Defining the molecular basis of oncogene-induced replication stress | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8317/grants?page=7